

01 March 2024

Biologic Medicines in Dermatology

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 44
- Adalimumab Biosimilar 203
- Apremilast 8
- Bimekizumab 9
- Brodalumab <5
- Certolizumab 8
- Deucravacitinib <5
- Dimethyl fumarate <5
- Etanercept – Enbrel <5
- Etanercept Biosimilar 7
- Guselkumab 86
- Infliximab – Remicade <5
- Infliximab Biosimilar 8
- Ixekizumab 60
- Risankizumab 87
- Secukinumab 41
- Tildrakizumab 6
- Ustekinumab 74
-

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.